Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium

The alfa pump® system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical ...